ES2819174T3 - Marcadores celulares para el diagnóstico de la enfermedad de Alzheimer y para la progresión de la enfermedad de Alzheimer - Google Patents

Marcadores celulares para el diagnóstico de la enfermedad de Alzheimer y para la progresión de la enfermedad de Alzheimer Download PDF

Info

Publication number
ES2819174T3
ES2819174T3 ES13767635T ES13767635T ES2819174T3 ES 2819174 T3 ES2819174 T3 ES 2819174T3 ES 13767635 T ES13767635 T ES 13767635T ES 13767635 T ES13767635 T ES 13767635T ES 2819174 T3 ES2819174 T3 ES 2819174T3
Authority
ES
Spain
Prior art keywords
lin
cd11b
cells
hla
low
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13767635T
Other languages
English (en)
Spanish (es)
Inventor
Michal Eisenbach-Schwartz
Ester Yoles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Neuroquest Ltd
Original Assignee
Yeda Research and Development Co Ltd
Neuroquest Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd, Neuroquest Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of ES2819174T3 publication Critical patent/ES2819174T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56972White blood cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES13767635T 2012-03-26 2013-03-21 Marcadores celulares para el diagnóstico de la enfermedad de Alzheimer y para la progresión de la enfermedad de Alzheimer Active ES2819174T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261615465P 2012-03-26 2012-03-26
PCT/IL2013/050277 WO2013144957A1 (en) 2012-03-26 2013-03-21 Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression

Publications (1)

Publication Number Publication Date
ES2819174T3 true ES2819174T3 (es) 2021-04-15

Family

ID=49258360

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13767635T Active ES2819174T3 (es) 2012-03-26 2013-03-21 Marcadores celulares para el diagnóstico de la enfermedad de Alzheimer y para la progresión de la enfermedad de Alzheimer

Country Status (10)

Country Link
US (1) US20150057176A1 (https=)
EP (1) EP2831584B1 (https=)
JP (1) JP6276252B2 (https=)
KR (1) KR20140145173A (https=)
CN (1) CN104471394B (https=)
AU (1) AU2013239070A1 (https=)
CA (1) CA2907909A1 (https=)
ES (1) ES2819174T3 (https=)
IL (1) IL234779A (https=)
WO (1) WO2013144957A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6312302B2 (ja) * 2014-01-06 2018-04-18 公益財団法人ヒューマンサイエンス振興財団 脳梗塞の診断マーカー
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
JP6499342B2 (ja) * 2018-03-19 2019-04-10 隆樹 日和佐 脳梗塞の診断マーカー
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
US20220170908A1 (en) * 2019-03-26 2022-06-02 Anton Wyss-Coray Compositions and methods for characterizing and treating alzheimers disease
CN111727260A (zh) * 2019-10-15 2020-09-29 湖南乾康科技有限公司 中间型单核细胞在制备诊断和预测ad药物中的应用
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
CN112562867A (zh) * 2021-02-22 2021-03-26 天津迈德新医药科技有限公司 一种预测极早期hiv感染风险的装置、存储介质和电子装置
KR20240042044A (ko) 2021-08-09 2024-04-01 뉴로퀘스트 엘티디 전임상 알츠하이머병을 검출하기 위한 조성물, 키트 및 방법
EP4426295A1 (en) * 2021-11-02 2024-09-11 Tranquis Therapeutics, Inc. Selection and treatment of subjects having a circulating myeloid cell inflammatory phenotype
KR102745500B1 (ko) * 2022-09-02 2024-12-23 한양대학교 에리카산학협력단 혈액 대사체를 이용한 치매 스크리닝 장치 및 방법
CN116270741B (zh) * 2023-02-28 2025-10-24 东莞市东南部中心医院 骨髓源性抑制细胞在制备治疗阿兹海默症药物或试剂中的应用
CN117122612B (zh) * 2023-07-07 2024-08-27 河络新图生物科技(上海)有限公司 外周血单个核细胞在制备治疗/预防阿尔茨海默病的药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1248643E (pt) * 2000-01-20 2005-10-31 Yeda Res & Dev Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora
US20020137108A1 (en) * 2000-11-08 2002-09-26 Michael Mullan CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker in alzheimer's disease
IL160105A0 (en) * 2001-12-06 2004-06-20 Yeda Res & Dev Vaccine for treatment of motor neurone diseases
CN100591761C (zh) * 2004-08-19 2010-02-24 加的夫大学学院咨询有限公司 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途
CN102186504B (zh) * 2008-09-18 2018-04-06 西塞医疗中心 用于检测阿尔兹海默病的光学方法
US20130230499A1 (en) * 2010-03-10 2013-09-05 Michal Eisenbach-Schwartz Cellular blood markers for early diagnosis of als and for als progression

Also Published As

Publication number Publication date
US20150057176A1 (en) 2015-02-26
EP2831584B1 (en) 2020-06-17
EP2831584A1 (en) 2015-02-04
CA2907909A1 (en) 2013-10-03
JP2015511721A (ja) 2015-04-20
JP6276252B2 (ja) 2018-02-07
IL234779A (en) 2017-12-31
WO2013144957A1 (en) 2013-10-03
CN104471394A (zh) 2015-03-25
KR20140145173A (ko) 2014-12-22
CN104471394B (zh) 2017-04-05
AU2013239070A1 (en) 2014-11-13
EP2831584A4 (en) 2015-10-07

Similar Documents

Publication Publication Date Title
ES2819174T3 (es) Marcadores celulares para el diagnóstico de la enfermedad de Alzheimer y para la progresión de la enfermedad de Alzheimer
Sugita et al. Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens
Boelen et al. Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function
Milo et al. Revised diagnostic criteria of multiple sclerosis
Calabrese et al. Exploring the origins of grey matter damage in multiple sclerosis
US20150209404A1 (en) Cellular blood markers for early diagnosis of als and for als progression
Chen et al. Type 1 diabetes patients have significantly lower frequency of plasmacytoid dendritic cells in the peripheral blood
Martins et al. Disease-specific expression of the serotonin-receptor 5-HT2C in natural killer cells in Alzheimer's dementia
Atkinson et al. Biological aging of CNS-resident cells alters the clinical course and immunopathology of autoimmune demyelinating disease
CN119971002A (zh) 多发性硬化症中的免疫优势蛋白和片段
Roda et al. Ataxia with oculomotor apraxia type 2 fibroblasts exhibit increased susceptibility to oxidative DNA damage
Frisullo et al. The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis
Fernandez et al. Murine Skin-resident γδT Cells Impair the Immune Response to HSV in Skin
Ma et al. Terminally differentiated cytotoxic CD4+ T cells were clonally expanded in the brain lesion of radiation‐induced brain injury
Ginaldi et al. Review on immunosenescence
Vitiligo Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases
Al-Khateeb Senescence and immune response after traumatic brain injury in juvenile and adult mice
Icduygu et al. Is there an association between NOD2 gene polymorphisms and chronic obstructive pulmonary disease progression
Alqurashi et al. Circulating and Mucosal Associated Type 2 Innate Lymphoid Cells in Asthma
Jiao et al. Confocal Corneal Microscopy in the Evaluation of Immune-related Motor Neuron Disease Syndrome
Monahan The Role of α-Synuclein-Specific T Cells in Parkinson’s Disease
Aljumah et al. Genetic variation among multiple sclerosis in Saudi patients
Burkitbayev et al. Distribution of HLA specificity in patients with acute lymphoblastic leukemia
EP2078960A1 (en) Method for determining the type of allergy
Vaknin et al. Excess Circulating Alternatively Activated Myeloid (M2) Cells Accelerate ALS Progression